Skip to content
  1. Home/
  2. Latest news/
  3. What you need to know about Johnson & Johnson’s 2018 third-quarter earnings
FINAL LEDE- What You Need to Know About Johnson & Johnson's 2018 Third-Quarter Earnings- stock illustration graphic

What you need to know about Johnson & Johnson’s 2018 third-quarter earnings

Learn how the company’s consumer, pharmaceutical and medical devices businesses performed in the third quarter of 2018 in this snapshot of its latest earnings report.

Johnson & Johnson shared financial information this morning about its third-quarter performance in 2018.
Since its founding in 1886, the company has grown to become one of the world’s largest and most broadly based healthcare companies, with approximately 135,000 employees across the globe working every day to help change the trajectory of health for humanity.

For more details about the company’s third-quarter 2018 results, and to read a message from Chairman and Chief Executive Officer Alex Gorsky, here’s an infographic packed with key stats.


3q2018-jj-earnings-infographic-web-final3.jpg

Johnson & Johnson’s 2018 3rd-Quarter Earnings

Read the earnings press release, which includes full financial data for the third quarter of the year.

Want to see more company earnings information? Find several years of Johnson & Johnson quarterly and full-year results here.

More from Johnson & Johnson

Inside Johnson & Johnson’s decades-long quest to develop effective treatments for IBD

Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.

The future of immunology

Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.

Using your own cells to fight cancer

Cell therapy is bringing the world one step closer to eliminating cancer. Here’s how Johnson & Johnson is moving this cutting-edge therapy forward.